- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
MSN Labs unveils Posaconazole for Black Fungus treatment in India
Hyderabad: MSN Laboratories on Friday announced the launch of Posaconazole, a triazole antifungal agent indicated for treating Black Fungus (Mucormycosis) patients, in India.
According to a press release issued by the company, MSN has launched the product under the brand name PosaOne as 100 mg Delayed Release tablets and 300 mg injections, respectively.
"As an outcome of MSN''s competence in research and manufacturing of anti-fungal infection drugs, it is now targeting to pro-actively reach patients across India by ensuring the access ofPosaOne, through its strong distribution network & field force," the city-based drug maker said.
MSN has developed the active pharmaceutical ingredient and the formulation of PosaOne in its in-house Research and Development and manufacturing units.
Read also: Torrent Pharma, Eli Lilly ink pact to boost Baricitinib production in India
The drug is approved by the Drug Controller General of India (DGCI) and matches the International quality standards.
As part of the COVID treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg, OSELOW (Oseltamivir) as 75 mg capsules and also licensed Baridoz (Baricitinib) recently with Eli Lilly.
Read also: MSN Labs unveils generic Favipiravir under brand name Favilow 800 mg at Rs 144 per tablet
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751